RxDoctor Payments Data

Barton Sickinger, DO

Cardiovascular Disease · Winter Park, FLNPI 1245223650

Payments from drug & device makers

$11,405in general payments, 2019–2025

Across 565 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AOP Health US, LLC$1K
  • Abbott$1K
  • Amarin Pharma, Inc.$808
  • Boehringer Ingelheim$730
  • Cvrx, Inc.$607
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$10,92096%
  • Education$4854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,405 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$600,440
Medicare patients
653
Services billed
3,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban355$400,584
XareltoRivaroxaban153$182,760
Repatha SureclickEvolocumab118$124,112
EntrestoSacubitril/Valsartan54$61,416
MultaqDronedarone Hcl15$21,134
NexlizetBempedoic Acid/Ezetimibe14$16,359
Praluent PenAlirocumab12$13,970
Flecainide Acetate253$11,029
Dabigatran EtexilateDabigatran Etexilate Mesylate21$7,581
Amiodarone Hcl112$4,335
Atorvastatin Calcium272$3,579
Metoprolol Succinate171$2,841
Losartan Potassium203$2,791
Prasugrel Hcl36$2,110
ClopidogrelClopidogrel Bisulfate116$2,031

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$446$400,584355 claims
Johnson & JohnsonXarelto$1,315$182,760153 claims
NovartisEntresto$355$61,41654 claims
Sanofi-aventis U.S. LLCMultaq$477$21,13415 claims
Esperion Therapeutics, Inc.Nexlizet$419$16,35914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →